TTR and poikiloderma with neutropenia: In the phase 3 NEURO-TTR trial [8], patients with ATTRv-PN receiving inotersen, an antisense oligonucleotide, exhibited slower progression of neuropathic symptoms, relative to patients receiving placebo, after 65 weeks of treatment, as measured by statistically significant treatment differences in change on the muscle weakness, sensation loss, and reflex subscales of the clinician-reported Neuropathy Impairment Score (NIS) and the NIS-Lower Limbs (NIS-LL), with the latter comprised of a subset of NIS items specific to the lower limbs [9].